NEW YORK MEDICAL COLLEGE
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 1860-01-01
- Employees
- 501
- Market Cap
- -
- Website
- http://www.nymc.edu
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
- First Posted Date
- 2015-03-19
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- New York Medical College
- Target Recruit Count
- 25
- Registration Number
- NCT02393157
- Locations
- 🇺🇸
New York Medical College, Valhalla, New York, United States
Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS
- Conditions
- Interventions
- First Posted Date
- 2014-08-20
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- New York Medical College
- Target Recruit Count
- 25
- Registration Number
- NCT02221310
- Locations
- 🇺🇸
New York Medical College, Valhalla, New York, United States
ODSH + ICE Chemotherapy in Pediatric Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2014-06-16
- Last Posted Date
- 2017-12-22
- Lead Sponsor
- New York Medical College
- Target Recruit Count
- 4
- Registration Number
- NCT02164097
- Locations
- 🇺🇸
New York Medical College, Valhalla, New York, United States
SCT Plus Immune Therapy in Average Risk AML/MDS
- Conditions
- Interventions
- First Posted Date
- 2014-04-17
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- New York Medical College
- Target Recruit Count
- 26
- Registration Number
- NCT02117297
- Locations
- 🇺🇸
New York Medical College, Valhalla, New York, United States
Study of Thyroid Hormones in Prematures
- Conditions
- Interventions
- First Posted Date
- 2014-04-04
- Last Posted Date
- 2019-04-24
- Lead Sponsor
- New York Medical College
- Registration Number
- NCT02103998
- Locations
- 🇺🇸
Maria Fareri Childrens Hospital, Valhalla, New York, United States
Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients
- Conditions
- Interventions
- First Posted Date
- 2014-03-28
- Last Posted Date
- 2022-10-27
- Lead Sponsor
- New York Medical College
- Target Recruit Count
- 20
- Registration Number
- NCT02098512
- Locations
- 🇺🇸
New York Medical College, Valhalla, New York, United States
3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2014-02-07
- Last Posted Date
- 2017-12-22
- Lead Sponsor
- New York Medical College
- Target Recruit Count
- 1
- Registration Number
- NCT02057445
- Locations
- 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸New York Medical College, Valhalla, New York, United States
Treatment for Advanced B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2013-05-22
- Last Posted Date
- 2022-10-25
- Lead Sponsor
- New York Medical College
- Target Recruit Count
- 45
- Registration Number
- NCT01859819
- Locations
- 🇺🇸
Levine Children's Hospital, Charlotte, North Carolina, United States
🇺🇸University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia
- First Posted Date
- 2013-04-30
- Last Posted Date
- 2022-10-25
- Lead Sponsor
- New York Medical College
- Target Recruit Count
- 41
- Registration Number
- NCT01842672
- Locations
- 🇺🇸
New York Medical College, Valhalla, New York, United States
🇺🇸Levine Children's Hospital, Charlotte, North Carolina, United States
Effect of Tetrabenazine on Stroop Interference in HD
- First Posted Date
- 2013-04-18
- Last Posted Date
- 2018-04-02
- Lead Sponsor
- New York Medical College
- Target Recruit Count
- 2
- Registration Number
- NCT01834911
- Locations
- 🇺🇸
Terence Cardinal Cooke Health Care Center, New York, New York, United States